In the past decades, the glycoconjugate vaccine has been proved to be a successful strategy for preventing infectious diseases. However, many diseases remain to be controlled, CD BioGlyco focuses on the development of methods for glycoconjugate vaccine design to timely develop tools needed to fight emerging infections and/or address currently unmet medical needs.
Glycoconjugate Vaccine
In contrast to the corresponding polysaccharide vaccines, glycoconjugate vaccines have diverse and complex structures, which include polysaccharide or oligosaccharide fragments linked to different carrier proteins through various coupling chemistries. Moreover, glycoconjugate vaccines overcome the limitations often associated with the use of unconjugated polysaccharide vaccines, such as the inability to evoke immune memory or the production of long-lived antibodies in children under 2 years old. The general structure of glycoconjugate vaccines is composed of carbohydrate B-cell epitopes and proteins or peptides that provide T-helper epitopes to ensure T-dependent memory response.